These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Rockwood K; Dai D; Mitnitski A Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382 [TBL] [Abstract][Full Text] [Related]
44. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. Kavanagh S; Howe I; Brashear HR; Wang D; van Baelen B; Todd M; Schwalen S Curr Alzheimer Res; 2011 Mar; 8(2):175-86. PubMed ID: 21222607 [TBL] [Abstract][Full Text] [Related]
45. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781 [TBL] [Abstract][Full Text] [Related]
46. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421 [TBL] [Abstract][Full Text] [Related]
47. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Chu LW; Yik PY; Mok W; Chung CP Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606 [TBL] [Abstract][Full Text] [Related]
48. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease. Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959 [TBL] [Abstract][Full Text] [Related]
49. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. van Dyck CH; Newhouse P; Falk WE; Mattes JA Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214 [TBL] [Abstract][Full Text] [Related]
51. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453 [TBL] [Abstract][Full Text] [Related]
52. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
53. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Farlow MR; Cyrus PA Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446 [TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. Imbimbo BP CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943 [TBL] [Abstract][Full Text] [Related]
55. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306 [TBL] [Abstract][Full Text] [Related]
56. Galantamine: a review of its use in Alzheimer's disease. Scott LJ; Goa KL Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124 [TBL] [Abstract][Full Text] [Related]
57. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713 [TBL] [Abstract][Full Text] [Related]
59. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I; JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594 [TBL] [Abstract][Full Text] [Related]
60. Galantamine treatment in outpatients with mild Alzheimer's disease. Richarz U; Gaudig M; Rettig K; Schauble B Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]